Boen L.R. Kam

Treatment With the Radiolabeled Somatostatin Analog [ ¹⁷⁷ Lu-DOTA ⁰ ,Tyr ³ ]Octreotate: Toxicity, Efficacy, and Survival

Dik J. Kwekkeboom, Wouter W. de Herder, Boen L.R. Kam et al. · Journal of Clinical Oncology · 2008 · 1.4K citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors

Tessa Brabander, Wouter A. van der Zwan, Jaap J.M. Teunissen et al. · Clinical Cancer Research · 2017 · 604 citations

Medicine, Oncology, Pharmacology +17

Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience

Roelf Valkema, Marion de Jong, Willem H. Bakker et al. · Seminars in Nuclear Medicine · 2002 · 433 citations

Medicine, Nuclear Medicine, Oncology +14

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate

Dik J. Kwekkeboom, Willem H. Bakker, Boen L.R. Kam et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2003 · 422 citations · Full text

Medicine, Nuclear Medicine, Oncology +10

Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course

Hendrik Bergsma, Mark Konijnenberg, Boen L.R. Kam et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2015 · 179 citations · Full text

Medicine, Hematology, Nuclear Medicine +16